The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change
European Journal of Cancer · 2024-11 · 212 · 115062
DOI: 10.1016/j.ejca.2024.115062 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-11. Verfasst von Susanne Singer und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology and Health Services Research, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical …. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Quality of Life. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, European Organisation for Research and Treatment of Cancer.
Abstract (Originalsprache)
INTRODUCTION: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment of Cancer head and neck cancer module, the EORTC QLQ-HN43, no such thresholds are established. METHODS: Head and neck cancer patients under active treatment (n = 503) from 15 countries completed the EORTC QLQ-HN43 three times (t1: before treatment, t2: three months after t1, t3: six months after t1). A subgroup completed a Subjective Significance Questionnaire (SSQ), indicating experienced change from the previous time point in four QoL domains. QoL was assumed to deteriorate after t1 and improve again until t3. The MIC was established using the average of mean differences in SSQ groups (MICmean) and estimates based on logistic regressions (MICpredict). Additionally, minimal detectable changes (MDC) were computed using 0.5 standard deviation and standard error of the mean. RESULTS: For swallowing, speech, dry mouth, and global QoL, the MIC for deterioration were 13, 14, 26, and 10 respectively. The MIC for improvement were 8 (swallowing), 6 (dry mouth), and 5 (global QoL); no MIC for speech improvement can be presented because of insufficient correlation between change score and anchor. The MDC estimates for deterioration were 15, 14, 15, and 11. For improvement, the MDC estimates were 13, 14, 14, and 11. CONCLUSIONS: Our results underline that no single MIC or MDC can be applied to all EORTC QLQ-HN43 scales, and that the MIC for deterioration seems larger than those for improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Epidemiology and Health Services Research, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Centre of Johannes Gutenberg University, Mainz, Germany. Electronic ad…
- Department of Otorhinolaryngology-Head and Neck Surgery, Institute of Clinical Sciences, SahlgrenskaAcademy at University of Gothenburg, SahlgrenskaUniversityHospital, Gothenburg, Sweden.
- Department of Medical Didactics, Jagiellonian University Medical College, Krakow, Poland.
- Department of Oncology, Oslo University Hospital, Norway; Department of Research Support Services, Oslo University Hospital, Norway.
- Department of Oral Surgery and Oral Medicine, University of Oslo, and Department of Otorhinolaryngology - Head and Neck Surgery Division for Head, Neck and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway.
- Radiation Oncology Department, Grupo CONFIAR, Goiania, GO, Brazil.
Förderung
- Japan Agency for Medical Research and Development
- European Organisation for Research and Treatment of Cancer
Zitieren
APA
Singer, S., Hammerlid, E., Tomaszewska, I. M., Amdal, C. D., Herlofson, B. B., Santos, M., Castro Silva, J., Mehanna, H., Fullerton, A., Young, T., Fernandez Gonzalez, L., Inhestern, J., Pinto, M., Arraras, J. I., Yarom, N., Bonomo, P., Baumann, I., Galalae, R., Nicolatou-Galitis, O., …, & EORTC Quality of Life Group and the EORTC Head and Neck Cancer Group (2024). The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change. European Journal of Cancer, 212, 115062. https://doi.org/10.1016/j.ejca.2024.115062
Vancouver
Singer S, Hammerlid E, Tomaszewska IM, Amdal CD, Herlofson BB, Santos M, et al. The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change. European Journal of Cancer. 2024;212:115062. doi:10.1016/j.ejca.2024.115062
BibTeX
@article{Singer2024,
author = {Singer, Susanne and Hammerlid, Eva and Tomaszewska, Iwona M and Amdal, Cecilie D and Herlofson, Bente B and Santos, Marcos and Castro Silva, Joaquim and Mehanna, Hisham and Fullerton, Amy and Young, Teresa and Fernandez Gonzalez, Loreto and Inhestern, Johanna and Pinto, Monica and Arraras, Juan I and Yarom, Noam and Bonomo, Pierluigi and Baumann, Ingo and Galalae, Razvan and Nicolatou-Galitis, Ourania and Kiyota, Naomi and Raber-Durlacher, Judith and Salem, Dina and Fabian, Alexander and Boehm, Andreas and Krejovic-Trivic, Sanja and Chie, Wei-Chu and Taylor, Katherine J and Sherman, Allen C and Licitra, Lisa and Machiels, Jean-Pascal and Bjordal, Kristin and EORTC Quality of Life Group and the EORTC Head and Neck Cancer Group, EORTC Quality of Life Group and the EORTC Head and Neck Cancer Group},
title = {The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change},
journal = {European Journal of Cancer},
year = {2024},
volume = {212},
pages = {115062},
doi = {10.1016/j.ejca.2024.115062}
}
EUVIMED